Production of Putative Enhanced Oral Cholera Vaccine Strains that Express Toxin-Coregulated Pilus by Hauke, Caitlyn A & Taylor, Ronald K
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
4-6-2017 
Production of Putative Enhanced Oral Cholera Vaccine Strains 
that Express Toxin-Coregulated Pilus 
Caitlyn A. Hauke 
Dartmouth College 
Ronald K. Taylor 
Dartmouth College 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medical Sciences Commons 
Dartmouth Digital Commons Citation 
Hauke, Caitlyn A. and Taylor, Ronald K., "Production of Putative Enhanced Oral Cholera Vaccine Strains 
that Express Toxin-Coregulated Pilus" (2017). Open Dartmouth: Published works by Dartmouth faculty. 
3127. 
https://digitalcommons.dartmouth.edu/facoa/3127 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
RESEARCH ARTICLE
Production of putative enhanced oral cholera
vaccine strains that express toxin-coregulated
pilus
Caitlyn A. Hauke*, Ronald K. Taylor†
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New




The use of whole cell killed (WCK) oral cholera vaccines is an important strategy for cholera
prevention in endemic areas. To overcome current vaccine limitations, we engineered
strains of V. cholerae to be non-toxigenic and to express the protective protein colonization
factor, toxin-coregulated pilus (TCP), under scale-up conditions potentially amenable to vac-
cine production. Two V. cholerae clinical strains were selected and their cholera toxin genes
deleted. The tcp operon was placed under control of a rhamnose-inducible promoter. Pro-
duction and stability of TCP were assessed under various conditions. The strains lack
detectable cholera toxin production. The addition of 0.1% rhamnose to the growth medium
induced robust production of TCP and TcpA antigen. The strains produced intact TCP in
larger growth volumes (1 L), and pili appeared stable during heat-killing or acid treatment of
the bacterial cultures. To date, no WCK cholera vaccines have included TCP. We have con-
structed putative strains of V. cholerae for use in a vaccine that produce high levels of stable
TCP antigen, which has not previously been achieved.
Introduction
Vibrio cholerae is a globally important pathogen, causing an estimated 2.8 million cases of
cholera and approximately 91,000 deaths in endemic countries, with an additional 87,000
cases and 2,500 deaths in non-endemic countries [1]. Although infection is treatable with rehy-
dration therapy, the explosive nature of outbreaks makes it difficult to treat infected patients
quickly and efficiently. Effective control measures rely on prevention and preparedness. Vac-
cines are a necessary component in preventing cholera.
Many cholera vaccine iterations have been explored throughout the last 125 years. In the
1960s, a parenteral cellular killed cholera vaccine proved to be effective against the disease in
adults, but resulted in a short protection period and caused reactogenic effects including fever
and swelling [2]. Another challenge posed by a parenteral vaccine is the requirement of trained
staff to use injection devices for administration [3]. Live-attenuated vaccines have also been
developed, and tend to generate more robust immunological responses with fewer doses, but
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pose risks of reactogenic effects and necessitate determining appropriate attenuation to main-
tain safety while retaining antigenicity (summarized in [3]). These vaccines also require a cold
chain, which is difficult to achieve in regions where electricity and other resources are limited.
An oral WCK vaccine is another option that has been studied in the effort to combat chol-
era. Currently, three such vaccines have been approved for human use. However, these oral
WCK vaccines (Dukoral, Shanchol, and Euvichol) offer incomplete protection for a limited
time in adults, and are less effective in children [3, 4]. These vaccines require two doses, two
weeks apart, with a booster every two years. For Dukoral, protective efficacy is 85% for up to 6
months and then rapidly declines [5]. For Shanchol, protection is approximately 67% for 2
years and lowers to 50% over 3–5 years [5, 6]. Euvichol is the newest cholera vaccine to become
prequalified by the World Health Organization and is comparable in protection to Shanchol
[4]. Additionally, children under 5 years do not mount strong clinical protection from these
vaccines and none of the vaccines are approved for use in children less than one year old [4, 6–
8]. These vaccines elicit an immune response primarily due to the presence of lipopolysaccha-
ride (LPS), a surface-exposed carbohydrate-based endotoxin. Young children, in general,
mount a less vigorous immune response to carbohydrate immunogens than to proteins [3].
Therefore, alternative vaccine preparations are needed.
Here we report engineered V. cholerae strains that express the toxin-coregulated pilus
(TCP), which is absent in currently licensed oral vaccine formulations, under the control of an
inducible promoter. A preparation that includes TCP, a colonization factor required for infec-
tion [9, 10], would provide an immunogenic protein that has been demonstrated to be a pro-
tective antigen [11–17]. Our putative vaccine strains consist of two V. cholerae O1 El Tor
variant biotype clinical isolates, one of the Ogawa and one of the Inaba serotype [18]. These
strains have been engineered with a rhamnose-inducible promoter controlling expression of
the tcp operon such that tcp gene expression can be uncoupled from the complex regulatory
cascade that controls its expression in wild-type strains. Our characterization of these strains
indicates their potential to help develop a new, possibly more effective WCK vaccine.
The adjustments made to the clinical isolate strains will allow for simplified preparation of
the WCK cholera vaccine, and more importantly, will permit the production and inclusion of
TCP in the vaccine, potentially enhancing it and improving efficacy. Particularly, we speculate
that the inclusion of TCP in a WCK cholera vaccine could offer more complete protection in
children.
Materials and methods
Bacterial strains and growth conditions
All strains and plasmids used in this study are described in Table 1.
All strains were maintained at -80˚C in lysogeny broth (LB) containing 20% glycerol (vol/
vol). Unless stated otherwise, V. cholerae strains grown under TCP-expressing conditions were
grown as follows: laboratory reference control O1 classical strains (O395 and O395ΔtcpA) were
grown in LB, starting pH of 6.5, with aeration at 30˚C for 12–16 h [19, 26]; El Tor and clinical
isolate strains (C6706str2, RM3, N6961, Bgd1, and Bgd5) were grown in AKI-inducing condi-
tions as previously described [27]; and vaccine strains (CAH182 and CAH184) were grown in
soy LB (traditional LB broth amended to replace tryptone with papain-digested soybean meal
(Spectrum Chemical Mfg. Corp., New Brunswick, NJ) to avoid prion risk from animal material)
with or without the addition of 0.1% rhamnose (vol/vol), as indicated, at 37˚C for 12–16 h.
When appropriate, strains were grown with antibiotics at the following final concentra-
tions: kanamycin 22.5 μg/ml or 45 μg/ml, polymixin B 25 μg/ml or 50 μg/ml, or with 20%
sucrose (vol/vol).
Enhanced cholera vaccine strains with TCP
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Plasmid and strain construction
Plasmids used in this study are listed in Table 1. Primers used for plasmid and strain construc-
tion are listed in S1 Table. To make cholera toxin deletions in clinical V. cholerae strains Bgd1
and Bgd5, pCHG041 was derived using the sucrose counter-selection plasmid pRE118 (ATCC1
87693™). Primers pairs RMF1/RMR1 and RMF2/RMR2 were used to amplify Bgd1/Bgd5 chro-
mosomal DNA outside of the ctx locus and the PCR amplified regions were then cloned into
pRE118. Using conventional allelic exchange techniques [10], the resulting ctx deletion con-
structs (CAH170 and CAH173) contained a 15 kb deletion of the ctx locus, which eliminated the
entire CTX genetic element (including ctxA and ctxB) and surrounding CTX-φ recognition
sequences (from VC1451 to VC1475). pCHG041, CAH173 (derivative of Bgd1), and CAH170
(derivative of Bgd5), were verified by DNA sequencing. Strain RM3, a derivative of C6706str2,
was produced in a similar manner (unpublished data).
To make the rhamnose-inducible tcp operon in the resulting “vaccine strains” (CAH182
and CAH184), plasmids were constructed in a step-wise manner. First, primers PEA002/026
were used to amplify a portion of tcpH upstream of the tcpA promoter in CAH173 and
CAH170, and PEA059/060 were used to amplify a portion of tcpA downstream from the pro-
moter in these strains. The amplified regions were cloned into pRE118 (ATCC1 87693™) to
produce pCHG042 and pCHG043, respectively, and plasmids were verified via DNA sequenc-
ing. Next, primers PEA027/028 were used to amplify the rhamnose promoter Prha from
Table 1. Strains or plasmids used in this study.
Strain or plasmid Description Reference or source
V. cholerae strains
O395 Classical, Ogawa, StrR Laboratory Collection [19]
CL101 O395 CTX-Kmφ; StrR/KmR Laboratory Collection [20]
O395ΔtcpA O395ΔtcpA, Classical, StrR Laboratory Collection [20]
N16961 El Tor, Inaba, StrR Laboratory Collection [21]
C6706str2 C6706, spontaneous StrR Laboratory Collection [10]
RM3 C6706str2, Δ15kbctx Laboratory Collection
Bgd1 El Tor Variant 01, Ogawa Laboratory Collection [18]
Bgd5 El Tor Variant 05, Inaba Laboratory Collection [18]
CAH170 Bgd5, Δ15kbctx This study
CAH173 Bgd1, Δ15kbctx This study
CAH182 CAH173, Prhatcp This study
CAH184 CAH170, Prhatcp This study
E. coli strains
BL21 F- ompT hsdS (rB-, mB) gal Laboratory Collection [22]
S17-1λpir recA, thi, pro, hsdR-M+ [RP4-2-Tc::Mu::KmR Tn7] (λpir); TpR StrR Laboratory Collection [23]
CC118λpir araD139Δ(ara leu)7697 ΔlacX74ΔphoA20 galK thi rpsE rpoB argE(Am) recA1 (λpir) Laboratory Collection [24]
Plasmids
pRE118 oriT oriV sacB aphA, KmR Laboratory Collection [25]
pCHG041 pRE118, 1035bp of Bgd1 to make Δ15kbctx in Bgd1, Bgd5 This study
pCHG042 pRE118, 1025bp of tcpH, tcpA of CAH173 to make Prhatcp This study
pCHG043 pRE118, 1025bp of tcpH, tcpA of CAH170 to make Prhatcp This study
pCHG046 pCHG042, 2093bp of RhaRSB of BL21 to make Prhatcp This study
pCHG047 pCHG043, 2093bp of RhaRSB of BL21 to make Prhatcp This study
Abbreviations: StrR—streptomycin resistance; KmR—kanamycin resistance; TpR—trimethoprim resistance.
https://doi.org/10.1371/journal.pone.0175170.t001
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Escherichia coli BL21 chromosomal DNA. The PCR amplified region was then cloned into
pCHG042 and pCHG043 to produce pCHG046 and pCHG047, respectively, and these plas-
mids were verified via DNA sequencing. The rhamnose-inducible promoter was incorporated
into CAH173 and CAH170 via allelic exchange to replace the native tcp promoter and produce
strains CAH182 (parent strain Bgd1) and CAH184 (parent strain Bgd5) using conventional
techniques [10]. Strains were verified with DNA sequencing. All DNA manipulations were
performed using standard molecular and genetic techniques [28].
Western immunoblotting and antisera
Whole-cell extracts (WCE) were assayed for total protein concentrations using a bicinchoninic
acid protein assay kit (ThermoFisher, Waltham, MA). Equal amounts of total protein for each
sample were resuspended in 2X sodium dodecyl sulfate-polyacrylamide gel electrophoresis
buffer and samples were boiled for 10 min prior to being loaded on 16% Tris-glycine poly-
acrylamide gel (Invitrogen, Carlsbad, CA). Proteins were transferred to a nitrocellulose mem-
brane via an iBlot dry blotting system (Invitrogen, Carlsbad, CA). The membrane was blocked
with 3% bovine serum albumin in 1X Tris-buffered saline with 0.1% Tween (TBST). Primary
antisera used included rabbit polyclonal antisera raised against TcpA [14], goat polyclonal for
CtxB (Millipore, Billerica, MA), mouse monoclonal antisera for Ogawa LPS (S-20-4) [29] and
for both Ogawa and Inaba LPS (72.1) [30]. Western immunoblots were visualized using the
ECL (Enhanced Chemiluminescence) detection system (GE Healthcare, Little Chalfont, Buck-
inghamshire, UK).
Samples of purified LPS and TcpA (from laboratory collection) were used as controls. Shan-
chol (Shantha Biotechnics, Andhra Pradesh, India) was provided by David Sack (Johns Hop-
kins, Baltimore, MD).
Cholera toxin production assay
GM1 ganglioside enzyme-linked immunosorbent CT assays (ELISAs) were performed on the
supernatants of cultures grown under AKI-inducing conditions or soy LB rhamnose-inducing
conditions, and the total ng of CT produced per ml of culture per OD600 unit (ng CT ml
−1
OD600
−1) was determined as previously described [31]. Purified cholera toxin B subunit (List
Biological Laboratories, Campbell, CA) was used as a standard.
Transmission electron microscopy (TEM)
Strains were grown under TCP-expressing conditions. A Formvar-coated copper grid (Elec-
tron Microscopy Supplies, Hatfield, PA) was inverted and suspended on top of a 50 μl drop
from an overnight culture or liquid preparation on Parafilm for 10 min. Grids were wicked
dry with Whatman filter paper, negatively stained with 0.5% phosphotungstic acid (pH 6.5)
for 2 min, and wicked dry again. Stained grids were stored in a desiccated chamber until view-
ing. Grids were viewed using a JEOL 100CX transmission electron microscope at 100kV at
magnifications up to 25,000X.
CTX-Kmφ transduction assay
Strains were grown under appropriate TCP-expressing conditions. The CTX-Kmφ transduc-
tion assay was performed as previously described [32]. Briefly, equal volumes of CTX-Kmφ-
containing supernatants and bacterial cultures were mixed and incubated in a water-bath at
37˚C for 45 min. Dilutions of each sample were plated on LB agar containing kanamycin.
Additionally, dilutions of bacterial cultures were plated to determine the number of input
Enhanced cholera vaccine strains with TCP
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bacteria. Transduction frequency was reported as the ratio of KmR test strain transductants to
the number of input CFUs divided by the ratio of KmR wild-type N16961 transductants to the
number of input CFUs. All strains were tested in three independent experiments and data are
reported as means with standard error bars.
Heat-killing and acid treatment of vaccine strains
To heat-kill vaccine strains, CAH182 and CAH184 were grown overnight in TCP-inducing
conditions with rhamnose. 1 mL aliquots of culture were centrifuged and pellets were resus-
pended in 200 μL 1X PBS. Microcentrifuge tubes were incubated in a dry block heater for up
to 120 min at 56˚C. For acid treatment of vaccine strains, again CAH182 and CAH184 were
grown in inducing conditions overnight, aliquoted, and centrifuged as described above. Pellets
were resuspended in 200 μL 1X PBS pH 2.0 and incubated in a water bath at 37˚C for up to
120 min.
Results
Current oral cholera vaccine formulations do not contain TCP
The toxin-coregulated pilus (TCP) is a filamentous surface component of V. cholerae that is
produced in significant quantities only under certain environmental conditions. While TCP
can be produced under specific laboratory cell growth conditions [19, 26, 27], the way in
which the V. cholerae strains contained in the oral, whole cell vaccine Shanchol are grown does
not result in production of TCP, as evidenced by a lack of the TCP major pilin protein TcpA
on a western immunoblot (Fig 1A, right side). It is thought that the primary immune response
to this vaccine is likely due to the abundance of the outer membrane carbohydrate complex
lipopolysaccharide (LPS) (Fig 1B).
Clinical variant strain selection for enhanced WCK cholera vaccine
Two Vibrio cholerae O1 El Tor variant biotype clinical strains were selected as candidate
strains to be included in an enhanced WCK cholera vaccine. While El Tor is the dominant
biotype in current cholera incidences, classical biotype features (typically genetically classi-
cal cholera toxin genes) have emerged in the form of hybrid El Tor variant strains [18, 33–
35]. These new pathogenic, clinically isolated variants have spread throughout Asian and
African countries, appear to cause more severe disease and higher cases of fatalities [5], and
are important to consider in future cholera vaccine development [36]. The selected strains
were isolated from patients at Matlab Hospital in Bangladesh and were originally obtained
from the International Center for Diarrheal Disease Research, Bangladesh (ICDDR,B) [18].
These strains, Bgd1 and Bgd5, caused severe dehydration and acute watery diarrhea in the
infected patients and produce high levels of cholera toxin (Fig 2A and 2B). Bgd1 and Bgd5
are Ogawa and Inaba serotypes, respectively (confirmed via western protein immunoblot in
S1 Fig), classified by variations in the O-antigenic component of LPS [37]. Both strains con-
tain a single copy of the cholera toxin genes (ctxA and ctxB) on the large chromosome only
[18].
Modified vaccine strains do not produce cholera toxin
After selection of the clinical variant strains, we first deleted the ctxA and ctxB genes, plus the
surrounding regions of the genome in each strain, resulting in a ~15 kb deletion of the ctx
locus (from VC1451 to VC1475). This deletion eliminates the entire CTX genetic element and
surrounding CTX-φ recognition sequences [32], such that CTX-φ cannot reincorporate the
Enhanced cholera vaccine strains with TCP
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cholera toxin genes back into the chromosome in the final vaccine strains. We confirmed the
absence of cholera toxin production in the final vaccine strains via GM1 ganglioside ELISA for
cholera toxin (Fig 2A) and western immunoblot for cholera toxin B protein (Fig 2B).
Fig 1. The Shanchol vaccine does not contain TcpA protein. A, Western immunoblot of TcpA protein present in ΔtcpA, wild-type N16961
(El Tor), clinical El Tor variant strains Bgd1 (Ogawa) and Bgd5 (Inaba), and rhamnose-inducible tcp strains in the Bgd1 and Bgd5 background
with cholera toxin genes deleted (referred to as CAH182 and CAH184, respectively; +R, with 0.1% rhamnose) as compared to the Shanchol
vaccine in ELISA units (EU). B, Western immunoblot of LPS present in these strains compared to Shanchol, probed with anti-LPS antiserum
72.1 (detects Ogawa and Inaba LPS).
https://doi.org/10.1371/journal.pone.0175170.g001
Enhanced cholera vaccine strains with TCP
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Vaccine strains contain rhamnose-inducible tcp and produce functional
pili
Following deletion of the cholera toxin genes, we placed the tcp operon under the control of
the E. coli rhamnose promoter by replacing the native V. cholerae tcp promoter with Prha from
E. coli strain BL21, thus placing expression of the tcp operon under control of rhamnose. This
approach allows for the inclusion of the protective antigen, TCP, in the vaccine formulation
simply by growing the bacteria in the presence of 0.1% rhamnose.
Fig 2. Vaccine strains do not produce cholera toxin. A, Cholera toxin production in the rhamnose-
inducible tcp strains, and ctx knockout strains CAH182 and CAH184 as compared to wild-type N16961, wild-
type C6706, RM3, which is the same ctx region deletion in the C6706 background, Bgd1 and Bgd5 strains.
ngCTml-1OD600
-1 ELISA measurements for three independent experiments presented as means with
standard errors. A two-tailed standard t test yielded P values of <0.05 when CTX production of Bgd1 (*) and
Bgd5 (*) were compared to all other strains. Bgd1 and Bgd5 were not significantly different from each other.
B, Western immunoblot of cholera toxin B subunit (CTXB) in the listed strains, thereby confirming deletion of
the genes encoding cholera toxin.
https://doi.org/10.1371/journal.pone.0175170.g002
Enhanced cholera vaccine strains with TCP
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To verify production of TCP that is dependent upon rhamnose addition, the final vaccine
strains CAH182 and CAH184 (parental strains are Bgd1 and Bgd5, respectively) were grown
in an animal-free medium (soy-based LB broth) at 37˚C overnight with or without the addi-
tion of 0.1% rhamnose (vol/vol). Whole cell extracts (WCE) were assayed via western immu-
noblot for the presence of TcpA, the major pilin that forms TCP, using anti-TcpA anti-serum.
Both CAH182 and CAH184 produced stable TcpA protein only when grown in the presence
of rhamnose (Fig 3A). Parental strains Bgd1 and Bgd5, along with control V. cholerae El Tor
strain N16961, only produced TcpA when grown in AKI-inducing conditions as previously
described [27] and did not produce TcpA in soy LB with or without the inclusion of rhamnose
(Fig 3A).
Additionally, pili production was evident in the rhamnose-induced vaccine strain cultures
when whole cell extracts were negatively stained with phosphotungstic acid (PTA) and viewed
using transmission electron microscopy (TEM) (Fig 3B).
Not only are pili produced by the induced vaccine strains, they are also functional, as dem-
onstrated via a phage transduction assay (Fig 3C) performed as previously described [32].
CAH182 and CAH184 were grown with and without 0.1% rhamnose in soy LB overnight at
37˚C, while control strains were grown in AKI-inducing conditions. Fig 3C shows that the vac-
cine strains are susceptible to CTX-Kmφ infection at high levels when tcp expression is
induced via rhamnose. The presence of TCP allows for uptake of the Km-resistant bacterio-
phage, which replicates as a plasmid [32], permitting growth of bacteria on LB agar containing
kanamycin.
TCP is produced in larger culture volumes
A consideration for vaccine production is expression of the antigens in large culture volume in
order to mass-produce the final vaccine formulation. To ensure that the rhamnose-inducible
strains CAH182 and CAH184 continue to produce TCP in larger culture volumes, we grew
1-liter overnight cultures of each bacterial strain induced with 0.1% rhamnose at 37˚C with
agitation. Fig 4A (western immunoblot for TcpA) and 4B (TEM images) show that the vaccine
strains CAH182 and CAH184, when grown in the presence of 0.1% rhamnose, produce TCP,
even if grown in larger volumes of soy LB medium at 37˚C, consistent with the strains poten-
tially being amendable for mass vaccine production.
TCP produced by vaccine strains can withstand heat-killing and acid
treatment
A possible cholera vaccine formulation would contain the strains CAH182 and CAH184
grown in tcp-expressing conditions, followed by heat-killing the strains at 56˚C for one hour.
To ensure heat-killing the bacteria does not disrupt the integrity of TCP, strains were grown in
inducing conditions overnight and whole cell extracts were centrifuged and resuspended in
PBS, followed by incubation of samples at 56˚C for 15, 30, 60, and 120 minutes. Heat-killing
was verified by plating approximately 5x1010 colony forming units (CFU) onto an LB agar
plate and incubating for 48 hours at 37˚C, followed by incubation at room temperature for an
additional four days. Zero CFU were recovered after the incubation period for all time points,
indicating killing of 100% of the bacteria in as little as 15 min at 56˚C (data not shown).
Heat-killed samples were then analyzed via SDS-PAGE and a western blot for TcpA indi-
cated that TcpA protein was stable for up to one hour after heat-killing (Fig 5A). Intact pili
were viewed via TEM in the 60 min killed samples (Fig 5B). However, at 120 min incubation
at 56˚C, TcpA levels were reduced by ~50% (Fig 5A) and few pili were visible by TEM (data
Enhanced cholera vaccine strains with TCP
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Fig 3. TcpA and pilus production in vaccine strains. A, Western immunoblot of TcpA production in rhamnose-inducible tcp, ctx
knockout strains CAH182 and CAH184 as compared to wild-type N16961, Bgd1 and Bgd5 strains under AKI-inducing conditions as
Enhanced cholera vaccine strains with TCP
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not shown). Regardless, 60 min at 56˚C was more than sufficient to ensure killing of the bacte-
rial strains while retaining TCP.
The integrity of TCP was also tested after incubation in an acidic environment to assess its
ability to withstand the acidic gastric environment encountered upon ingestion of an oral chol-
era vaccine. Overnight, induced cultures of the vaccine strains were centrifuged and resus-
pended in PBS with a pH of 2. The samples were incubated in the acidic PBS for 15, 30, 60,
and 120 minutes at 37˚C. Western immunoblot analysis and TEM imaging showed that acid
compared to growth in soy LB (traditional lysogeny broth amended to replace tryptone with papain-digested soybean meal to avoid prion
risk from animal material) with or without addition of 0.1% rhamnose. B, Transmission electron microscopy of phosphotungstic acid-
negatively stained pili produced by CAH182 (left) and CAH184 (right) after growth in soy LB with 0.1% rhamnose. C, CTX-Kmϕ phage
transduction via TCP in wild-type N16961, Bgd1 and Bgd5 in AKI growth conditions and vaccine strains CAH182 and CAH184 with (+R)
and without (-R) 0.1% rhamnose grown in soy LB. Data from three independent experiments +/- standard errors. A two-tailed standard t
test yielded no significant differences among strains.
https://doi.org/10.1371/journal.pone.0175170.g003
Fig 4. Vaccine strains produce TCP in 1L growth volumes. A, Western immunoblot analysis of TcpA from
CAH182 and CAH184 induced with 0.1% rhamnose (+R) in soy LB grown in large (1L) volumes. B, Pili produced by
CAH182 (left) and CAH184 (right) in the above conditions as seen with transmission electron microscopy and
negative staining.
https://doi.org/10.1371/journal.pone.0175170.g004
Enhanced cholera vaccine strains with TCP
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treatment did not disrupt the stability of TcpA nor the integrity of whole pili for all incubation
periods (Fig 5C and 5D, respectively).
Discussion
We have developed strains of V. cholerae that show potential to be used in a new oral, whole
cell killed cholera vaccine that includes two clinical isolate O1 El Tor variant strains, an
Ogawa and Inaba serotype, each containing cholera toxin gene deletions and a rhamnose-
inducible tcp operon, such that a vaccine can be prepared that is non-toxigenic and includes
the protective antigen toxin-coregulated pilus following culture in an animal-free medium
supplemented with 0.1% rhamnose in addition to the cell wall antigens found in the current
killed oral vaccines. This strategy simplifies the way in which the vaccine is prepared, as
existing vaccine formulations contain some cholera toxin that needs to be removed during
preparation of the formulations [3], while our vaccine strains are entirely devoid of cholera
toxin. Additionally, the vaccine strains, CAH182 and CAH184, produce robust, functional
pili when induced with rhamnose. This antigen is completely lacking in the currently avail-
able WCK formulations. Our strains are also potentially amenable for scaled-up vaccine
production, as TCP is still produced in larger culture volumes. Further assessment of TCP
production as a result of bacterial growth in larger bioreactors would reaffirm the potential
for successful scale-up production, but was not performed for this study. Moreover, because
the whole tcp operon is induced, other TCP proteins will be expressed, such as the novel
and more recently discovered colonization factor, TcpF, which, like TCP, is required for
infection [20, 38]. These strains also express two serotypes of LPS from the most widespread
V. cholerae strains. Experiments comparing the putative TCP-enhanced vaccine strains to
non-TCP expressing V. cholerae strains in an animal model would be an important follow
up to this preliminary study.
The final vaccine formulation can be easily prepared by heat-killing the strains for one hour
at 56˚C, which we have shown does not disrupt the integrity of the pili produced in the vol-
umes tested. This finding is unlike the current inactivated cholera vaccines, which contain
both heat-killed and formalin-killed strains, and necessitate the removal of the formalin used
in production [3]. We have also shown in this study that exposure to an acidic environment,
reminiscent of the gastric environment that would be encountered by an oral vaccine, does not
disrupt the integrity of the pili produced in the vaccine. This observation indicates that the
TCP would remain intact during passage through the stomach.
Our putative vaccine strains should result in increased efficacy due to the presence of TCP,
especially, we hope, in children that do not mount an effective immune response against car-
bohydrate antigens, which represent the protective antigen (LPS) component in the current
vaccines [3]. Although children do not mount a good immune response to carbohydrates, they
do to proteins like TCP, which suggests a WCK vaccine comprised of our V. cholerae strains
could prove more effective for populations under 5 years of age compared to current formula-
tions. Furthermore, an enhanced WCK vaccine containing additional protective antigens
could lead to higher protection and efficacy in adults as well.
Fig 5. Pili produced by vaccine strains are stable after incubation in high heat or an acidic medium. A, Western immunoblot analysis for TcpA after
heat-killing of the vaccine strains CAH182 and CAH184 at 56˚C over two hours following overnight growth in soy LB with 0.1% rhamnose (+R) at 37˚C. B,
Transmission electron microscopy results of the negatively-stained pili after heat-killing for 60 minutes (CAH182, left and CAH184, right). C, Western
immunoblot analysis of TcpA after treatment of the vaccine strains CAH182 and CAH184 with acid (pH 2.0) up to two hours at 37˚C after overnight growth
in soy LB at 37˚C with 0.1% rhamnose (+R). D, Transmission electron microscopy results of negatively-stained pili after treatment with acid for 120 minutes
(CAH182, left and CAH184, right).
https://doi.org/10.1371/journal.pone.0175170.g005
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S1 Fig. Western immunoblot analysis of LPS of wild-type O395, wild-type N16961, Bgd1
and Bgd5, and the vaccine strains CAH182 and CAH184, confirming Ogawa and Inaba
serotypes. LPS-antibody S-20-4 reacts with Ogawa serotype only (left), while the 72.1 antibody
binds both Ogawa and Inaba serotypes (right).
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